Quarterly ResultAug 3, 2026, 04:04 PM
Keros Therapeutics Q2 Net Loss $28.7M; Initiates Rinvatercept Phase 2 Trial
AI Summary
Keros Therapeutics reported a net loss of $28.7 million for the second quarter of 2026, an improvement from a $30.7 million net loss in the prior year. The company also announced the initiation of a Phase 2 clinical trial for rinvatercept in Duchenne muscular dystrophy patients, with initial data anticipated in the first half of 2027. Significant decreases in R&D and G&A expenses were noted due to the transition of elritercept-related R&D to Takeda and a 2025 corporate restructuring. Keros expects its $257.6 million in cash and cash equivalents to fund operations into the first half of 2028.
Key Highlights
- Q2 2026 net loss of $28.7 million, down from $30.7 million in Q2 2025.
- Research and development expenses decreased to $22.3 million from $43.5 million YoY.
- General and administrative expenses decreased to $8.6 million from $14.5 million YoY.
- Cash and cash equivalents totaled $257.6 million as of June 30, 2026.
- Cash runway expected to fund operations into the first half of 2028.
- Initiated Phase 2 clinical trial for rinvatercept in Duchenne muscular dystrophy.
- Expects initial Phase 2 rinvatercept data in the first half of 2027.
Price Impact
More from KROS